CS
TVTX icon

Credit Suisse’s Travere Therapeutics TVTX Stock Holding History

Credit Suisse’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$792K Buy
102,710
+766
+0.8% +$6.46K ﹤0.01% 2403
2023
Q4 		$916K Buy
101,944
+40,316
+65% +$294K ﹤0.01% 2385
2023
Q3 		$551K Sell
61,628
-25,049
-29% -$353K ﹤0.01% 2628
2023
Q2 		$1.33M Buy
86,677
+33,015
+62% +$601K ﹤0.01% 2193
2023
Q1 		$1.21M Buy
53,662
+8,351
+18% +$178K ﹤0.01% 2212
2022
Q4 		$953K Sell
45,311
-1,444
-3% -$30.6K ﹤0.01% 2374
2022
Q3 		$1.15M Buy
46,755
+4,574
+11% +$118K ﹤0.01% 2228
2022
Q2 		$1.02M Sell
42,181
-2,973
-7% -$74.8K ﹤0.01% 2361
2022
Q1 		$1.16M Sell
45,154
-970
-2% -$25.8K ﹤0.01% 2451
2021
Q4 		$1.43M Buy
46,124
+6,172
+15% +$174K ﹤0.01% 3041
2021
Q3 		$970K Buy
39,952
+6,877
+21% +$126K ﹤0.01% 3369
2021
Q2 		$482K Sell
33,075
-2,518
-7% -$49.7K ﹤0.01% 3867
2021
Q1 		$889K Sell
35,593
-25,316
-42% -$699K ﹤0.01% 3399
2020
Q4 		$1.66M Buy
60,909
+7,748
+15% +$181K ﹤0.01% 2962
2020
Q3 		$982K Sell
53,161
-13,102
-20% -$255K ﹤0.01% 2947
2020
Q2 		$1.35M Buy
66,263
+30,449
+85% +$485K ﹤0.01% 2693
2020
Q1 		$523K Sell
35,814
-5,972
-14% -$89.9K ﹤0.01% 3081
2019
Q4 		$593K Buy
41,786
+7,374
+21% +$94.2K ﹤0.01% 3455
2019
Q3 		$399K Buy
34,412
+9,514
+38% +$157K ﹤0.01% 3560
2019
Q2 		$500K Sell
24,898
-9,096
-27% -$180K ﹤0.01% 3410
2019
Q1 		$769K Buy
33,994
+2,076
+7% +$45.9K ﹤0.01% 3089
2018
Q4 		$723K Sell
31,918
-29,378
-48% -$731K ﹤0.01% 3041
2018
Q3 		$1.76M Buy
61,296
+16,871
+38% +$482K ﹤0.01% 2447
2018
Q2 		$1.21M Sell
44,425
-17,142
-28% -$456K ﹤0.01% 2868
2018
Q1 		$1.38M Buy
61,567
+14,676
+31% +$350K ﹤0.01% 2730
2017
Q4 		$989K Sell
46,891
-8,360
-15% -$191K ﹤0.01% 3004
2017
Q3 		$1.38M Buy
55,251
+22,989
+71% +$506K ﹤0.01% 2868
2017
Q2 		$624K Sell
32,262
-24,763
-43% -$449K ﹤0.01% 3002
2017
Q1 		$1.05M Buy
57,025
+4,407
+8% +$86.2K ﹤0.01% 2825
2016
Q4 		$996K Buy
52,618
+2,971
+6% +$60.8K ﹤0.01% 3029
2016
Q3 		$1.11M Sell
49,647
-20,453
-29% -$389K ﹤0.01% 2862
2016
Q2 		$1.25M Buy
70,100
+15,032
+27% +$243K ﹤0.01% 2735
2016
Q1 		$752K Buy
55,068
+1,417
+3% +$21.5K ﹤0.01% 2941
2015
Q4 		$1.03M Buy
53,651
+21,323
+66% +$426K ﹤0.01% 2789
2015
Q3 		$656K Sell
32,328
-38,537
-54% -$1.14M ﹤0.01% 3190
2015
Q2 		$2.35M Buy
70,865
+1,456
+2% +$39.9K ﹤0.01% 2429
2015
Q1 		$1.66M Buy
69,409
+38,326
+123% +$584K ﹤0.01% 2545
2014
Q4 		$381K Buy
31,083
+4,061
+15% +$42K ﹤0.01% 3902
2014
Q3 		$244K Buy
27,022
+10,390
+62% +$122K ﹤0.01% 4037
2014
Q2 		$195K Sell
16,632
-40,825
-71% -$553K ﹤0.01% 4379
2014
Q1 		$1.22M Buy
+57,457
New +$883K ﹤0.01% 2954

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Credit Suisse's TVTX Position: Q1 2024 in Review

Credit Suisse increased its Travere Therapeutics (TVTX) stake by 0.75% in Q1 2024, buying an estimated $6.46K and bringing the position to 102,710 shares worth $792K. The position accounts for ﹤0.01% of the portfolio, ranked #2403.

Credit Suisse first reported a position in TVTX in Q1 2014 and has held it in 41 quarters since. The position peaked at $2.35M in Q2 2015. 175 funds tracked by Wall St. Rank hold TVTX as of Q1 2024.

  • Credit Suisse held 102,710 shares of Travere Therapeutics worth $792K as of Q1 2024.
  • Credit Suisse bought 766 Travere Therapeutics shares in Q1 2024, an estimated $6.46K.
  • Travere Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2403 holding.
  • Credit Suisse first reported a position in Travere Therapeutics in Q1 2014 and has held it in 41 quarters since.
  • Credit Suisse's Travere Therapeutics position peaked at $2.35M in Q2 2015.
  • 175 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.